Bone health check after first stem cell transplant in AML
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Hormones & metabolism clinical trials.
This study looks at how a bone-strengthening measure (bone mineral density and bone structure) changes over time after an allogeneic stem cell transplant for acute myeloid leukemia (AML). It may help doctors better understand transplant-related bone effects and how to monitor them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML and you are planned for your first “allogeneic” (donor) stem cell transplant.
- You can attend all study visits and follow the transplant-study procedures as required.
- You can give informed consent (you understand the study and agree to take part).
- If you can become pregnant, you will use reliable birth control throughout the study and avoid pregnancy.
- You are not currently pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This trial tests if a bone-strengthening medicine called zoledronate can help prevent bone problems in children and teens who have had a stem cell transplant. It may be an option for patients with low bone density or those who develop graft-versus-host disease after transplant.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
Hear when a new Myeloid Leukemia, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.